Clock

Clock

Re-recognition here runs through printed quarters, not one event. The 59% fall from $367.87 to $150.12 was a multiple collapse, not an earnings cut — estimates rose the whole way down. The mechanisms that would close the gap are already turning: a $50 billion buyback running at management's stated low prices, revenue guided back to double digits by 2H FY2027, and an AI-cannibalization fear the Agentforce and seat numbers have not confirmed. Its one comparable drawdown took 28 months to round-trip.

What would close the gap

The dislocation is unusual for this framework: the price fell 59% while the earnings line kept rising. Consensus EPS for the current fiscal year was revised up by 44 analysts and down by none over the trailing 30 days, and the company has beaten every quarter since early FY2025. So the gap is not a broken number waiting to be repaired — it is a compressed multiple. At $170.77 against consensus FY2027 EPS of $14.13, the stock trades near 12 times forward earnings, a level it has not held in its public life. Four mechanisms can re-rate it, each with a date attached.

The buyback shrinks the denominator — now, at management's stated "low prices." In September 2025 the Board lifted the repurchase authorization to a $50.0 billion aggregate under a program running since August 2022 [1]. On the Q4 FY2026 call, management framed the acceleration explicitly against the sell-off — "this obviously is not a rational market… that's why we are doing this incredible repurchase authorization of $50 billion… these are some low prices" — and reported returning more than $14 billion, or 99% of free cash flow, to shareholders in FY2026 [2]. At the current $163.3 billion market cap, $14 billion of annual capital return retires roughly 8.6% of the equity each year, and the share count has already fallen from 997 million (FY2023) to 956 million (FY2026). This is the most mechanical of the four: it compounds intrinsic value per share on a quarterly cadence regardless of when sentiment turns.

Growth is guided to reaccelerate to double digits by the second half of FY2027. Management reaffirmed on the Q4 call a path "towards double-digit revenue growth by the second half of fiscal year '27," on the back of FY2026 revenue of $41.5 billion (+10%), CRPO of $35.1 billion (+16%), and total RPO of $72 billion (+14%) [3]. The counter-fact sits in the same call: CRPO growth of 9% was called "somewhat disappointing" by an analyst, and current-year revenue growth has decelerated from 11.2% (FY2024) to 8.7% (FY2025) before the guided reacceleration. The second half of FY2027 is the window where that guidance either prints or fails.

The feared event — AI agents cannibalizing seat-based software — has not shown up in the numbers. The bear narrative that de-rated the stock holds that Agentforce displaces the seats Salesforce sells. The company's own disclosure runs the other way so far: Agentforce reached roughly an $800 million business with 29,000 deals closed in its first 15 months, up 50% quarter-over-quarter, and customers in production up nearly 50% in Q4 [4], with management stating seats "are continuing to grow" [5]. A fear disproven in print is the classic re-rating trigger; the test dates are the next several earnings calls.

Multiple normalization is the residual. With the numbers intact, a re-rating from ~12x forward earnings requires only that the market stop pricing the AI thesis as terminal. That is not a dated catalyst — it is what the three mechanisms above are meant to force.

The dated catalyst path

Sources: earnings dates from the consensus earnings calendar (as reported); guidance milestone from the Q4 FY2026 earnings call [6]. Dreamforce window is the company's historical September–October cadence.

Capital allocation is not confined to repurchases: the Board also approved a 5.8% increase in the quarterly dividend on the same call [7], so the buyback tailwind is not being diverted to debt paydown at the moment it matters most.

Base rates from Salesforce's own history

Over its full listed history since 2004, Salesforce has drawn down 30% or more nine times. Two prior episodes match the current one in depth (roughly 55–70%); the rest were shallower and faster. The pattern that matters: the one directly comparable episode — a growth-multiple de-rate rather than a macro crash — took the longest to repair.

Source: derived from the run's daily price history, 2004–2026 (as reported). Depth = (trough close − peak close) / peak close.

Source: derived from the run's daily price history (as reported). Round-trip = peak date to the first close back at the prior peak; the current episode has not round-tripped.

The arithmetic the skeptic can recompute: the current drawdown ran from a $367.87 close on 2024-12-04 to a $150.12 close on 2026-06-22 — a 59.2% decline over 565 days, the longest peak-to-trough grind in the name's history. The stock has recovered to $170.77, about 13.8% off the trough, with the low set roughly a month before this reading. The closest analog is 2021–22: a 58.6% fall over 403 days that took 844 days — about 28 months — to round-trip to its prior high. The deeper 2008 episode round-tripped faster (about 18 months) but was a market-wide crash, not a Salesforce-specific narrative. What this name has not done in twenty years is round-trip a 55%-plus, company-specific de-rate inside 18 months.

Volume confirmed the selling was capitulation: peak-to-trough daily volume ran 3.5 times the pre-peak median (see Dislocation).

The 18-month test

Read against the mechanism and the base rate: partial re-recognition within 18–24 months is a reasonable expectation, but a full round-trip to the prior high inside that window is not what this name's history supports. The buyback compounds per-share value every quarter, consensus already models the forward free-cash-flow yield clearing 9.1% (FY2027) and 10.0% (FY2028) on the current market cap, and the growth reacceleration has a management-dated milestone in the second half of FY2027 — so the ingredients for the multiple to stop compressing are in place on an 18-month clock. But the one comparable episode in the record took roughly 28 months to fully repair, and the current drawdown only troughed about a month before this reading; the honest characterization is printed-quarter cycle repair over roughly two years, with the buyback doing the compounding in the interim, rather than a fast snapback. What would falsify this read: the guided double-digit reacceleration failing to print in the second half of FY2027, CRPO growth continuing to decelerate below 9%, or seat counts inflecting down as agents displace them — the framework's repricing-cycle and FCF-sliding falsifiers, tied to the ledger in Fit.

What consensus expects, and when

The sell side has not capitulated — and that cuts both ways. Fifty-two analysts carry a mean price target of $245.16 and a median of $238.03 against the $170.77 price, implying 40% upside, with a $475 high and a $160 low. Recommendations run 40 buy or strong-buy, 10 hold, and 2 strong-sell out of 52.

Source: consensus analyst estimates and price targets, as reported (CapIQ / consensus feed).

Under this framework, that reads two ways. The favorable reading: consensus forward free cash flow independently clears the yield bar (9.1% FY2027, 10.0% FY2028), so the sell side agrees on value while the buy side is the party that fled — the setup the framework prefers. The unfavorable reading: with 77% of analysts already at buy and targets already 40% above the price, the capitulated-street signal is absent. There is little upgrade fuel left in the sell side; the re-rating has to come from the buy side re-engaging with printed evidence, not from a wave of upgrades. The recommendation mix has in fact softened only slightly over three months (strong-buys 8 to 6), so the analysts largely never left.

As for when consensus expects the recovery in printed numbers: the estimates already show it. Consensus models FY2027 revenue of $46.1 billion (+11.0%) and EPS of $14.13 (+12.8%), then FY2028 revenue of $50.5 billion and EPS of $15.53. The numbers are not expected to fall and then recover — they are expected to keep rising. The candidate quarter for a re-rating is therefore the one that validates the guided reacceleration rather than any trough: the Q3 FY2027 print in early December 2026 and the Q4 FY2027 print in late February 2027, when "double-digit growth by the second half of FY2027" is either on the tape or it is not.

The instrument facts

These are facts, stated as facts — no strikes, no sizing, no advice.

Long-dated listed options exist on Salesforce, one of the most heavily traded single-name option chains in the US market. January 2028 LEAPS were listed on 15 September 2025 and, as of this reading in July 2026, sit roughly 18 months out, alongside the shorter January 2027 series; open interest and daily volume on the name are among the deepest in large-cap software, so long-dated liquidity is not a constraint. The framework's watchlist-only case (qualifying long-dated options absent) does not apply here — they exist.

On implied volatility: AlphaQuery reported Salesforce's 30-day implied volatility (calls) at 49.83% for 2026-07-21, with a separate reading in early July near 43–44% and above the 52-week median. That places current implied volatility at roughly 45–50% — the upper edge of the reference band this framework treats as acceptable (up to ~50–55), not yet in the elevated 60–70 zone. For context, 30-day realized volatility from the run's own price data was 37.9% on 2026-07-17, so options carry a modest premium to realized — consistent with an unresolved AI-narrative and an earnings date on 2 September 2026. Implied volatility is not estimated here; the figures above are the dated readings found, and they will move.